SMS Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 26, 2026, 2:55 am

Market Cap	3,567 Cr.
Current Price	381
Intrinsic Value	₹302.90
High / Low	388/175
Stock P/E	40.9
Book Value	81.2
Dividend Yield	0.11 %
ROCE	12.2 %
ROE	11.0 %
Face Value	1.00
PEG Ratio	11.59

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for SMS Pharmaceuticals Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	122 Cr.	97.2	137/84.3	25.3	49.6	0.00 %	12.9 %	9.69 %	10.0
MPS Pharmaa Ltd	3.15 Cr.	1.65	3.69/1.60		0.33	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	3,447 Cr.	316	479/208	72.1	24.3	0.21 %	27.3 %	21.7 %	1.00
Gujarat Terce Laboratories Ltd	30.2 Cr.	38.8	79.8/37.2		10.1	0.00 %	41.4 %	14.6 %	10.0
Gujarat Inject (Kerala) Ltd	94.5 Cr.	64.5	64.7/17.0	378	6.93	0.00 %	13.5 %	11.0 %	10.0
Industry Average	20,665.44 Cr	1,107.58		56.62	201.21	0.37%	16.35%	15.16%	6.10

All Competitor Stocks of SMS Pharmaceuticals Ltd

Quarterly Result

Metric	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	159	149	149	135	167	161	246	164	197	173	248	196	242
Expenses	146	131	126	109	139	133	212	131	165	140	207	157	194
Operating Profit	14	18	23	27	28	29	33	33	32	33	41	39	48
OPM %	9%	12%	16%	20%	17%	18%	14%	20%	16%	19%	17%	20%	20%
Other Income	1	2	1	1	1	1	2	1	1	2	1	1	1
Interest	5	6	6	6	6	6	6	5	5	4	5	6	6
Depreciation	8	8	8	8	8	8	8	8	9	9	9	10	10
Profit before tax	1	6	11	13	15	16	22	22	20	23	29	24	34
Tax %	12%	22%	24%	29%	21%	26%	26%	25%	28%	24%	29%	24%	26%
Net Profit	1	5	8	9	12	12	16	16	14	17	21	18	25
EPS in Rs	0.09	0.59	0.95	1.10	1.42	1.44	1.88	1.93	1.68	2.03	2.33	2.05	2.68

Last Updated: December 29, 2025, 2:32 am

Below is a detailed analysis of the quarterly data for SMS Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Sales, as of Sep 2025, the value is 242.00 Cr.. The value appears strong and on an upward trend. It has increased from 196.00 Cr. (Jun 2025) to 242.00 Cr., marking an increase of 46.00 Cr..
For Expenses, as of Sep 2025, the value is 194.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 157.00 Cr. (Jun 2025) to 194.00 Cr., marking an increase of 37.00 Cr..
For Operating Profit, as of Sep 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Jun 2025) to 48.00 Cr., marking an increase of 9.00 Cr..
For OPM %, as of Sep 2025, the value is 20.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 20.00%.
For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
For Interest, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 10.00 Cr..
For Profit before tax, as of Sep 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Jun 2025) to 34.00 Cr., marking an increase of 10.00 Cr..
For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 26.00%, marking an increase of 2.00%.
For Net Profit, as of Sep 2025, the value is 25.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 7.00 Cr..
For EPS in Rs, as of Sep 2025, the value is 2.68. The value appears strong and on an upward trend. It has increased from 2.05 (Jun 2025) to 2.68, marking an increase of 0.63.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 10:15 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	518	587	611	438	463	465	412	563	520	522	709	783	897
Expenses	461	500	522	363	369	375	332	442	405	467	592	643	725
Operating Profit	57	86	89	75	93	90	80	121	115	55	117	140	172
OPM %	11%	15%	15%	17%	20%	19%	19%	22%	22%	10%	16%	18%	19%
Other Income	2	16	4	1	2	3	5	3	5	5	4	6	7
Interest	14	18	17	16	15	12	12	11	19	22	24	19	23
Depreciation	13	17	19	19	20	19	22	22	32	32	32	34	38
Profit before tax	32	67	56	42	60	62	51	91	69	6	66	93	118
Tax %	36%	48%	26%	14%	33%	34%	36%	33%	1%	26%	25%	27%
Net Profit	20	35	42	36	40	41	33	61	68	4	49	68	87
EPS in Rs	2.40	4.15	4.92	4.20	4.78	4.89	3.86	7.20	8.03	0.48	5.83	7.71	9.55
Dividend Payout %	8%	5%	4%	5%	5%	5%	6%	4%	4%	62%	7%	5%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	75.00%	20.00%	-14.29%	11.11%	2.50%	-19.51%	84.85%	11.48%	-94.12%	1125.00%	38.78%
Change in YoY Net Profit Growth (%)	0.00%	-55.00%	-34.29%	25.40%	-8.61%	-22.01%	104.36%	-73.37%	-105.59%	1219.12%	-1086.22%

SMS Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	3%
5 Years:	14%
3 Years:	15%
TTM:	10%

Compounded Profit Growth
10 Years:	7%
5 Years:	16%
3 Years:	0%
TTM:	24%

Stock Price CAGR
10 Years:	17%
5 Years:	22%
3 Years:	39%
1 Year:	-31%

Return on Equity
10 Years:	11%
5 Years:	10%
3 Years:	7%
Last Year:	11%

Last Updated: September 5, 2025, 1:31 pm

Balance Sheet

Last Updated: December 4, 2025, 2:00 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	8	8	8	8	8	8	8	8	8	8	8	9	9
Reserves	213	246	286	254	293	331	359	420	485	487	562	664	751
Borrowings	167	167	204	149	146	144	157	255	263	254	281	311	324
Other Liabilities	120	119	158	89	72	93	103	147	126	165	217	202	221
Total Liabilities	509	540	656	501	519	577	627	830	883	914	1,068	1,186	1,305
Fixed Assets	247	277	370	290	279	281	280	457	438	412	437	533	517
CWIP	39	29	13	8	8	18	42	7	11	33	30	35	50
Investments	6	13	21	37	45	45	45	45	45	45	45	45	48
Other Assets	217	221	252	166	187	232	259	321	389	424	556	573	690
Total Assets	509	540	656	501	519	577	627	830	883	914	1,068	1,186	1,305

Below is a detailed analysis of the balance sheet data for SMS Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
For Reserves, as of Sep 2025, the value is 751.00 Cr.. The value appears strong and on an upward trend. It has increased from 664.00 Cr. (Mar 2025) to 751.00 Cr., marking an increase of 87.00 Cr..
For Borrowings, as of Sep 2025, the value is 324.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 311.00 Cr. (Mar 2025) to 324.00 Cr., marking an increase of 13.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 221.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 202.00 Cr. (Mar 2025) to 221.00 Cr., marking an increase of 19.00 Cr..
For Total Liabilities, as of Sep 2025, the value is 1,305.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,186.00 Cr. (Mar 2025) to 1,305.00 Cr., marking an increase of 119.00 Cr..
For Fixed Assets, as of Sep 2025, the value is 517.00 Cr.. The value appears to be declining and may need further review. It has decreased from 533.00 Cr. (Mar 2025) to 517.00 Cr., marking a decrease of 16.00 Cr..
For CWIP, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 15.00 Cr..
For Investments, as of Sep 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Mar 2025) to 48.00 Cr., marking an increase of 3.00 Cr..
For Other Assets, as of Sep 2025, the value is 690.00 Cr.. The value appears strong and on an upward trend. It has increased from 573.00 Cr. (Mar 2025) to 690.00 Cr., marking an increase of 117.00 Cr..
For Total Assets, as of Sep 2025, the value is 1,305.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,186.00 Cr. (Mar 2025) to 1,305.00 Cr., marking an increase of 119.00 Cr..

Notably, the Reserves (751.00 Cr.) exceed the Borrowings (324.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	65	59	61	73	32	50	40	90	45	22	50	82
Cash from Investing Activity +	-37	-55	-79	-39	-17	-35	-43	-152	-27	-30	-52	-123
Cash from Financing Activity +	-30	-10	27	-33	-15	-13	-2	92	-12	-32	31	47
Net Cash Flow	-2	-6	9	1	0	2	-5	31	6	-39	29	5

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-110.00	-81.00	-115.00	-74.00	-53.00	-54.00	-77.00	-134.00	-148.00	-199.00	-164.00	-171.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	39	37	36	18	19	20	43	68	34	104	122	95
Inventory Days	90	81	106	114	135	170	191	148	333	243	201	238
Days Payable	59	58	79	82	49	59	66	70	97	117	130	95
Cash Conversion Cycle	70	61	63	50	105	131	169	146	270	230	192	238
Working Capital Days	9	19	19	-2	27	39	57	48	94	104	85	88
ROCE %	12%	21%	16%	13%	18%	16%	13%	17%	12%	4%	11%	12%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	64.29%	64.32%	64.32%	64.32%	64.67%	64.67%	64.67%	64.67%	66.27%	66.27%	68.07%	68.07%
FIIs	0.59%	0.67%	0.60%	0.59%	0.17%	0.18%	0.52%	0.31%	0.08%	0.03%	0.28%	0.04%
DIIs	0.00%	0.00%	0.00%	0.00%	1.98%	2.13%	2.55%	2.55%	2.43%	3.03%	2.88%	3.21%
Public	35.12%	35.01%	35.07%	35.10%	33.18%	33.03%	32.27%	32.47%	31.23%	30.68%	28.77%	28.69%
No. of Shareholders	25,537	24,653	25,246	25,341	30,140	31,780	33,136	34,973	35,332	33,652	34,157	34,378

Shareholding Pattern Chart

No. of Shareholders

SMS Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Quant Small Cap Fund	1,859,681	0.22	58.88	N/A	N/A	N/A
Quant Healthcare Fund	908,071	8.44	28.75	1,118,647	2026-02-21 09:12:10	-18.82%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	8.16	5.89	-0.83	7.35	7.39
Diluted EPS (Rs.)	8.16	5.89	-0.83	7.35	7.39
Cash EPS (Rs.)	11.48	9.54	4.25	11.82	9.83
Book Value[Excl.RevalReserv]/Share (Rs.)	72.15	63.36	54.40	55.56	48.50
Book Value[Incl.RevalReserv]/Share (Rs.)	72.15	63.36	54.40	55.56	48.50
Revenue From Operations / Share (Rs.)	88.29	83.79	61.67	61.41	66.53
PBDIT / Share (Rs.)	16.38	14.30	7.02	14.12	14.71
PBIT / Share (Rs.)	12.51	10.58	3.22	10.32	12.08
PBT / Share (Rs.)	10.42	7.81	0.63	8.09	10.76
Net Profit / Share (Rs.)	7.60	5.81	0.45	8.02	7.20
NP After MI And SOA / Share (Rs.)	7.80	5.89	-0.83	7.35	7.39
PBDIT Margin (%)	18.55	17.07	11.37	22.99	22.11
PBIT Margin (%)	14.16	12.62	5.22	16.80	18.16
PBT Margin (%)	11.79	9.32	1.02	13.17	16.17
Net Profit Margin (%)	8.61	6.93	0.74	13.05	10.82
NP After MI And SOA Margin (%)	8.83	7.02	-1.35	11.96	11.10
Return on Networth / Equity (%)	10.80	9.29	-1.53	13.23	15.23
Return on Capital Employeed (%)	13.38	12.75	4.36	13.17	16.54
Return On Assets (%)	5.99	4.81	-0.80	7.23	7.69
Long Term Debt / Equity (X)	0.21	0.22	0.26	0.31	0.36
Total Debt / Equity (X)	0.48	0.52	0.54	0.55	0.53
Asset Turnover Ratio (%)	0.71	0.74	0.60	0.61	0.78
Current Ratio (X)	1.72	1.62	1.61	1.92	1.59
Quick Ratio (X)	0.84	0.91	0.73	0.64	0.88
Inventory Turnover Ratio (X)	3.02	1.86	1.26	1.99	2.35
Dividend Payout Ratio (NP) (%)	4.89	5.09	-35.97	4.08	0.00
Dividend Payout Ratio (CP) (%)	3.27	3.12	10.13	2.69	0.00
Earning Retention Ratio (%)	95.11	94.91	135.97	95.92	0.00
Cash Earning Retention Ratio (%)	96.73	96.88	89.87	97.31	0.00
Interest Coverage Ratio (X)	7.83	5.16	2.71	6.33	11.16
Interest Coverage Ratio (Post Tax) (X)	4.64	3.10	1.18	4.60	6.46
Enterprise Value (Cr.)	2151.85	1748.52	734.33	1007.49	1231.25
EV / Net Operating Revenue (X)	2.75	2.47	1.41	1.94	2.19
EV / EBITDA (X)	14.82	14.44	12.36	8.43	9.88
MarketCap / Net Operating Revenue (X)	2.41	2.13	0.93	1.53	1.87
Retention Ratios (%)	95.10	94.90	135.97	95.91	0.00
Price / BV (X)	2.95	2.81	1.06	1.69	2.57
Price / Net Operating Revenue (X)	2.41	2.13	0.93	1.53	1.87
EarningsYield	0.03	0.03	-0.01	0.07	0.05

After reviewing the key financial ratios for SMS Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 25, the value is 8.16. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 8.16, marking an increase of 2.27.
For Diluted EPS (Rs.), as of Mar 25, the value is 8.16. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 8.16, marking an increase of 2.27.
For Cash EPS (Rs.), as of Mar 25, the value is 11.48. This value is within the healthy range. It has increased from 9.54 (Mar 24) to 11.48, marking an increase of 1.94.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.15. It has increased from 63.36 (Mar 24) to 72.15, marking an increase of 8.79.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.15. It has increased from 63.36 (Mar 24) to 72.15, marking an increase of 8.79.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 88.29. It has increased from 83.79 (Mar 24) to 88.29, marking an increase of 4.50.
For PBDIT / Share (Rs.), as of Mar 25, the value is 16.38. This value is within the healthy range. It has increased from 14.30 (Mar 24) to 16.38, marking an increase of 2.08.
For PBIT / Share (Rs.), as of Mar 25, the value is 12.51. This value is within the healthy range. It has increased from 10.58 (Mar 24) to 12.51, marking an increase of 1.93.
For PBT / Share (Rs.), as of Mar 25, the value is 10.42. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 10.42, marking an increase of 2.61.
For Net Profit / Share (Rs.), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 5.81 (Mar 24) to 7.60, marking an increase of 1.79.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.80. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 7.80, marking an increase of 1.91.
For PBDIT Margin (%), as of Mar 25, the value is 18.55. This value is within the healthy range. It has increased from 17.07 (Mar 24) to 18.55, marking an increase of 1.48.
For PBIT Margin (%), as of Mar 25, the value is 14.16. This value is within the healthy range. It has increased from 12.62 (Mar 24) to 14.16, marking an increase of 1.54.
For PBT Margin (%), as of Mar 25, the value is 11.79. This value is within the healthy range. It has increased from 9.32 (Mar 24) to 11.79, marking an increase of 2.47.
For Net Profit Margin (%), as of Mar 25, the value is 8.61. This value is within the healthy range. It has increased from 6.93 (Mar 24) to 8.61, marking an increase of 1.68.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 7.02 (Mar 24) to 8.83, marking an increase of 1.81.
For Return on Networth / Equity (%), as of Mar 25, the value is 10.80. This value is below the healthy minimum of 15. It has increased from 9.29 (Mar 24) to 10.80, marking an increase of 1.51.
For Return on Capital Employeed (%), as of Mar 25, the value is 13.38. This value is within the healthy range. It has increased from 12.75 (Mar 24) to 13.38, marking an increase of 0.63.
For Return On Assets (%), as of Mar 25, the value is 5.99. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 5.99, marking an increase of 1.18.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.22 (Mar 24) to 0.21, marking a decrease of 0.01.
For Total Debt / Equity (X), as of Mar 25, the value is 0.48. This value is within the healthy range. It has decreased from 0.52 (Mar 24) to 0.48, marking a decrease of 0.04.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has decreased from 0.74 (Mar 24) to 0.71, marking a decrease of 0.03.
For Current Ratio (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has increased from 1.62 (Mar 24) to 1.72, marking an increase of 0.10.
For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 0.91 (Mar 24) to 0.84, marking a decrease of 0.07.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.02. This value is below the healthy minimum of 4. It has increased from 1.86 (Mar 24) to 3.02, marking an increase of 1.16.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.89. This value is below the healthy minimum of 20. It has decreased from 5.09 (Mar 24) to 4.89, marking a decrease of 0.20.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.27. This value is below the healthy minimum of 20. It has increased from 3.12 (Mar 24) to 3.27, marking an increase of 0.15.
For Earning Retention Ratio (%), as of Mar 25, the value is 95.11. This value exceeds the healthy maximum of 70. It has increased from 94.91 (Mar 24) to 95.11, marking an increase of 0.20.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.73. This value exceeds the healthy maximum of 70. It has decreased from 96.88 (Mar 24) to 96.73, marking a decrease of 0.15.
For Interest Coverage Ratio (X), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 5.16 (Mar 24) to 7.83, marking an increase of 2.67.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.64. This value is within the healthy range. It has increased from 3.10 (Mar 24) to 4.64, marking an increase of 1.54.
For Enterprise Value (Cr.), as of Mar 25, the value is 2,151.85. It has increased from 1,748.52 (Mar 24) to 2,151.85, marking an increase of 403.33.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.75. This value is within the healthy range. It has increased from 2.47 (Mar 24) to 2.75, marking an increase of 0.28.
For EV / EBITDA (X), as of Mar 25, the value is 14.82. This value is within the healthy range. It has increased from 14.44 (Mar 24) to 14.82, marking an increase of 0.38.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.41, marking an increase of 0.28.
For Retention Ratios (%), as of Mar 25, the value is 95.10. This value exceeds the healthy maximum of 70. It has increased from 94.90 (Mar 24) to 95.10, marking an increase of 0.20.
For Price / BV (X), as of Mar 25, the value is 2.95. This value is within the healthy range. It has increased from 2.81 (Mar 24) to 2.95, marking an increase of 0.14.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.41, marking an increase of 0.28.
For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of SMS Pharmaceuticals Ltd as of February 26, 2026 is: ₹292.58

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 26, 2026, SMS Pharmaceuticals Ltd is Overvalued by 23.21% compared to the current share price ₹381.00

Intrinsic Value of SMS Pharmaceuticals Ltd as of February 26, 2026 is: ₹302.90

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 26, 2026, SMS Pharmaceuticals Ltd is Overvalued by 20.50% compared to the current share price ₹381.00

Last 5 Year EPS CAGR: 3.53%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (411.62 cr) compared to borrowings (217.08 cr), indicating strong financial stability. The company has shown consistent growth in sales (576.00 cr) and profit (62.54 cr) over the years.	The stock has a low average ROCE of 13.75%, which may not be favorable. The stock has a high average Working Capital Days of 48.92, which may not be favorable. The stock has a high average Cash Conversion Cycle of 143.75, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in SMS Pharmaceuticals Ltd:
1. Net Profit Margin: 8.61%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 13.38% (Industry Average ROCE: 16.35%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 10.8% (Industry Average ROE: 15.16%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 4.64
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.84
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 40.9 (Industry average Stock P/E: 56.62)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.48
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

SMS Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 14/12/1987 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24239TG1987PLC008066 and registration number is 008066. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 782.75 Cr. and Equity Capital is Rs. 8.87 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Plot No. 72, H.No. 8-2-334 / 3 & 4, Road No. 5, Opp. SBI Executive Enclave, Hyderabad Telangana 500034	Contact not found

Management
Name	Position Held
Mr. Ramesh Babu Potluri	Chairman & Managing Director
Mr. Vamsi Krishna Potluri	Executive Director
Dr. Sunkara Venkata Satya Shiva Prasad	Non Exe.Non Ind.Director
Mr. Trilok Potluri	Non Exe.Non Ind.Director
Mr. Sarvepalli Srinivas	Ind. Non-Executive Director
Mr. Sharvan Kudaravalli	Ind. Non-Executive Director
Dr. Suresh Kumar Gangavarapu	Ind. Non-Executive Director
Mrs. Shanti Sree Bolleni	Ind. Non-Executive Director

FAQ

What is the intrinsic value of SMS Pharmaceuticals Ltd?

SMS Pharmaceuticals Ltd's intrinsic value (as of 26 February 2026) is ₹302.90 which is 20.50% lower the current market price of ₹381.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,567 Cr. market cap, FY2025-2026 high/low of ₹388/175, reserves of ₹751 Cr, and liabilities of ₹1,305 Cr.

What is the Market Cap of SMS Pharmaceuticals Ltd?

The Market Cap of SMS Pharmaceuticals Ltd is 3,567 Cr..

What is the current Stock Price of SMS Pharmaceuticals Ltd as on 26 February 2026?

The current stock price of SMS Pharmaceuticals Ltd as on 26 February 2026 is ₹381.

What is the High / Low of SMS Pharmaceuticals Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of SMS Pharmaceuticals Ltd stocks is ₹388/175.

What is the Stock P/E of SMS Pharmaceuticals Ltd?

The Stock P/E of SMS Pharmaceuticals Ltd is 40.9.

What is the Book Value of SMS Pharmaceuticals Ltd?

The Book Value of SMS Pharmaceuticals Ltd is 81.2.

What is the Dividend Yield of SMS Pharmaceuticals Ltd?

The Dividend Yield of SMS Pharmaceuticals Ltd is 0.11 %.

What is the ROCE of SMS Pharmaceuticals Ltd?

The ROCE of SMS Pharmaceuticals Ltd is 12.2 %.

What is the ROE of SMS Pharmaceuticals Ltd?

The ROE of SMS Pharmaceuticals Ltd is 11.0 %.

What is the Face Value of SMS Pharmaceuticals Ltd?

The Face Value of SMS Pharmaceuticals Ltd is 1.00.